Eliquis FDA Approval History
FDA Approved: Yes (First approved December 28, 2012)
Brand name: Eliquis
Generic name: apixaban
Dosage form: Tablets
Company: Bristol-Myers Squibb Company and Pfizer Inc.
Treatment for: Prevention of Thromboembolism in Atrial Fibrillation, Deep Vein Thrombosis Prophylaxis after Knee Replacement Surgery, Deep Vein Thrombosis Prophylaxis after Hip Replacement Surgery
Eliquis (apixaban) is a factor Xa inhibitor anticoagulant indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery.
Development timeline for Eliquis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.